SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

Autologous, CAR-T, CD19

February 19, 2021

Yescarta's Median Time to CRS Improved by Prophylactic Corticosteroid Use; Thoughts on Frank Neumann Joining Kite as Worldwide Head of Clinical Development

Here is a brief preview of this blast: On Wednesday, February 10, Gilead (Kite) announced (press release / abstract) updated results from cohort 6 of the Ph1/2 ZUMA-1 trial. The analysis showed that prophylactic use of corticosteroids has the potential to delay Yescarta’s CRS onset. Additionally, Gilead announced (press release) that Frank Neumann has joined Kite as Senior Vice President and Global Head of Clinical Development. Below, Celltelligence provides insights on how Yescarta’s improved safety profile could bring CRS onset parity with Breyanzi and if Kite’s recent senior management appointments could suggest a reprioritization towards solid tumors.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.